NASDAQ:HCM

HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda(R) in China) for Advanced Pancreatic Neuroendocrine Tumors

HONG KONG, June 21, 2021 /PRNewswire/ --  HUTCHMED (China) Limited ("HUTCHMED ") (Nasdaq/AIM: HCM) today announces that surufatinib has been granted approval for drug registration by the National Medical Products Administration ofChina ("NMPA") for the treatment of adv...

2021-06-21 15:15 3280

Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-06-07 08:00 6741

International companies to host live webcasts at Deutsche Bank's June 9th and 10th Depositary Receipts Virtual Investor Conference

NEW YORK, June 6, 2016 /PRNewswire/ -- Deutsche Bank today announced the lineup for itsJune 9th and 10th Depositary Receipts Virtual Investor Conference ("dbVIC"), featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US. Represe...

2016-06-06 21:00 3307

Hutchison China MediTech to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on June 10, 2016

HONG KONG, June 6, 2016 /PRNewswire/ -- Hutchison China MediTech (LONDON STOCK EXCHANGE: HCM, NASDAQ: HCM) based inChina, and globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products, today announced that Chief Execu...

2016-06-06 20:30 2028

Week's Top Stories